贝伐珠单抗|T9904|TargetMol

Bevacizumab
216974-75-3

￥3370 5mg 起订

￥1990 2mg 起订

￥1320 1mg 起订

上海更新日期：2024-12-02

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 贝伐珠单抗

英文名称：: Bevacizumab

CAS号：: 216974-75-3

品牌：: TargetMol

产地：: 美国

保存条件：: store at low temperature | store at -20°C | Shipping with blue ice.

纯度规格：: CE-SDS:97.5% SEC-HPLC:98.0%

产品类别：: 抑制剂

货号：: T9904

Product Introduction

Bioactivity

名称	Bevacizumab
描述	Bevacizumab is a humanized monoclonal antibody targeting VEGF that specifically binds to VEGF, blocks VEGR binding to VEGFR, and inhibits the angiogenic signaling pathway. Bevacizumab has antitumor activity and can inhibit tumor cell growth.
细胞实验	Human umbilical vein endothelial cells (HUVECs) (1×104 cells/100 μL/well) are seeded in 96-well plates and cultured at 37 for 14 h with Endothelial Cell Medium supplemented with 5% heat-inactivated FCS, 100 U/mL Penicillin, 100 U/mL Streptomycin, and endothelial cell growth supplement. After low-serum starvation overnight, cells are treated with different concentrations of FD006 or Bevacizumab which are pre-incubated with 10 ng/mL VEGF for 30 minutes and incubated at 37, 5% CO2 for 72 hours. Then, 10 μL CCK8 is added to each well and incubated for another 4 hours. The absorbance is measured by spectrophotometer at 450 nm to determine the cell viability[2].
激酶实验	The binding kinetics of Bevacizumab or FD006 to VEGF is measured using Bio-Layer Inter-Ferometry on Octet RED. The assay is conducted at 30°C in PBS buffer. Sensor tips are pre-wet for 15 mins in buffer immediately prior to use, and the microplates are filled with 200 μL per well of diluted samples (VEGF) or buffer and agitated at 1000 rpm. The anti-human IgG biosensor are pre-saturated with Bevacizumab or FD006 (10 μg/mL) and washed in buffer for 120 seconds, and then transferred to VEGF at concentrations of 10 μg/mL, 3 μg/mL and 1 μg/mL. The VEGF association and dissociation rates are measured for 5mins and 10mins, respectively. The Kinetics parameters (Kon and Koff) and affinities (KD) are calculated from a non-linear global fit using the Octet analysis software. Multiple independent measurements are performed[2].
体外活性	方法：人肺癌细胞 A549 用 Bevacizumab (1-25 µM) 处理 12-72 h，使用 CCK-8 assay 检测细胞增殖。结果：Bevacizumab 治疗 A549 细胞 12 h，显示出对细胞增殖的轻度抑制，但 24 h 后显示出以剂量依赖性方式显著诱导细胞凋亡。[1] 方法：人肿瘤细胞 AGS、Caco2 和 HepG2/C3A 用 Bevacizumab (5 ng/mL-100 µg/mL) 处理 48 h，使用半定量 RT-PCR 检测端粒酶表达和活性。结果：Bevacizumab (5 ng/mL) 使 AGS 中的 hTERT mRNA 水平增加 35.2%，Caco2 增加 62.0%，HepG2/C3A 增加 21.8%。而 Bevacizumab (100 µg/mL) 使 AGS 中的 hTERT mRNA 水平增加 42.3%，Caco2 增加 94.1%，HepG2/C3A 增加 52.5%。因此，Bevacizumab 显著增加了AGS、Caco2 和 HepG2/C3A 中的 hTERT mRNA 水平和端粒酶活性。[2]
体内活性	方法：为研究抗肿瘤活性，将 Bevacizumab (2-5 mg/kg) 腹腔注射给携带人骨肉瘤细胞 143B-RFP 异种移植物的裸鼠，每周两次，持续 43 天。结果：Bevacizumab 在裸鼠模型的实验性骨肉瘤中表现出强大的抗血管生成活性，但不影响肺转移的发生率。[3]
存储条件	store at low temperature \| store at -20°C \| Shipping with blue ice.
关键字	Bevacizumab
相关产品	Ribociclib \| Lenvatinib \| Axitinib \| Sorafenib tosylate \| Lenvatinib mesylate \| Sanguinarine chloride \| Regorafenib \| Pazopanib \| Nintedanib \| Sorafenib \| Regorafenib monohydrate \| Taxifolin

贝伐珠单抗|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子